PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis

Pierre Quartier ,M Hofer,S Oliveira,Kiran Nistala ,Müferet Ergüven ,K Lheritier ,Shai Padeh ,Tilmann Kallinich ,Laurence Goffin ,Nicolino Ruperto ,Carine Wouters ,T Constantin ,Josef Hruska ,Inmaculada Calvo ,Stefania Viola ,Ken Abrams ,Hermine I Brunner ,Alberto Martini ,Yosef Uziel ,Dj Lovell

doi:10.1186/1546-0096-11-s2-p169

Abstract

Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Efficacy and safety of canakinumab (CAN), a selective, fully human, anti- IL-1β monoclonal antibody, have been demonstrated in 2 phase III trials. Here we present 12-week results of a post-hoc pooled analysis.

Highlights

Interleukin-1b (IL-1b) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA)
The post-hoc analysis presented here focuses on SJIA response to CAN therapy in the initial treatment period of a total of 178 CAN-naïve pts
Methodological factors precluded a comparator group, so this analysis is of a descriptive nature

Summary

Introduction

Interleukin-1b (IL-1b) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Efficacy and safety of canakinumab (CAN), a selective, fully human, anti- IL-1b monoclonal antibody, have been demonstrated in 2 phase III trials. We present 12-week results of a post-hoc pooled analysis

Methods

Results

Conclusion